title: Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas.
abstract: HER2 / neu is a potential antigen candidate for immunotherapy because of its correlation to a poor prognosis and high expressions in many kinds of epithelial tumours. Especially in the colorectal carcinomas, the higher expression of HER2 / neu is recognized in metastatic regions as well as in primary sites. Several CTL epitopes restricted by HLA-A2.1 and -A3 were identified so far, however epitopes restricted by HLA-A24, that is one of the most common allele in Japanese and Caucasians, have not been identified. In this paper, we showed identification of a CTL epitope peptide of HER2 / neu restricted by HLA-A24. HLA-A24 binding peptides selected by an analysis based on HLA-A24 binding motifs were determined for their binding affinities to HLA-A24 molecules. The peptide with a sequence of RWGLLLALL (position 8-16) named HE1 showed the highest affinity. We induced CTLs from CD8(+)cells of HLA-A24 healthy donors by stimulation with HE1-pulsed autologous dendritic cells. The CTLs showed cytotoxic activity against not only the peptide-pulsed target cells but also HLA-A24 colorectal tumour cell lines that endogenously overexpressed HER2 / neu. The antigen-specificity was confirmed by cold target inhibition assay using HE1-pulsed target cells. In summary, HER2 / neu peptide, RWGLLLALL, may contribute to the induction of antitumour immunity with the peptide-based immunotherapy for the colorectal carcinomas.
authors.affiliation: Department of Surgery II, Wakayama Medical School, Wakayama, 641-0012, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Tsunoda
authors.forename: I
authors.initials: I
authors.lastname: Nukaya
authors.forename: A
authors.initials: A
authors.lastname: Sette
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Umano
authors.forename: H
authors.initials: H
authors.lastname: Yamaue
authors.forename: K
authors.initials: K
authors.lastname: Takesako
authors.forename: H
authors.initials: H
authors.lastname: Tanimura
mesh_terms: D015179:Colorectal Neoplasms / Q000628:therapy*; D003713:Dendritic Cells / Q000276:immunology*; D018604:Epitope Mapping / Q000379:methods*; D015234:HLA-A Antigens / Q000276:immunology*; D059871:HLA-A24 Antigen; D006801:Humans; D007167:Immunotherapy; D010449:Peptide Mapping; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases